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Background: The efﬁcacy of Tyrosine Kinake inhibitors (TKIs) of 
EGFR is associated with well characterized mutations on the exons 18, 
19 and 21 of EGFR gene. Less common mutations could be detected in 
these exons but their relationship with the clinical efﬁcacy of TKIs has 
not been established yet. 
Methods: Genomic DNA was extracted from microdissected formalin-
ﬁxed parafﬁn-embeded tumor tissue from 86 pts enrolled in a geﬁtinib 
expanded access program. Exons 18, 19 and 21 were ampliﬁed and 
subjected to direct sequencing. 
Results: Classical EGFR mutations (CM) were detected in 9 (10.4%) 
pts and other mutations variants (MV) in 19 (22%) pts. Eight (42.1%) 
MV were observed in exon 18, 3 (15.8%) in exon 19 and 8 (42.1%) 
in exon 21. Tumor Growth Control (TGC) was achieved in 88.9% 
(3PR and 5SD) pts with CM, 63% (2PR and 10SD) pts with MV and 
in 45.9% (3PR and 25SD) pts with wild type EGFR gene (WT). There 
was no clear association between the presence of EGFR MV and the 
sex, histology or smoking history. The median TTP was 64 weeks 
(range:4-80+), 20 weeks (range:6-140) and 16 weeks (range:4-176+) 
in pts with CM, MV and WT, respectively. Nine (47.3%) pts with 
EGFR MV had a TTP >24 weeks. The median survival was 78 weeks 
(range:5-94+), 70 weeks (range:10-142) and 36 weeks (range:4-176+) 
in pts with CM, MV and WT, respectively. Three patients bearing 
mutations in exons 18, 19, and 21 progressed despite geﬁtinib treat-
ment suggesting that these mutations could be related to resistance to 
geﬁtinib. 
Conclusions: EGFR mutation variants could be associated with 
response or resistance to TKIs but their low incidence requires their 
evaluation in a largest cohort of patients. 
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Background: Surgery improved the results of treatment for stage IIIA 
non small cell lung cancer (NSCLC). However, a signiﬁcant fraction 
of patients after surgical resection die due to local or systemic re-
lapses. Nonetheless, the best adjuvant therapy to improve survival and 
decrease relapse rate remains as an ever controversial issue. There-
fore, we conducted a randomized trial to determine whether or which 
postoperative adjuvant therapy is beneﬁcial in prolonging survival and 
decreasing recurrence in patients with completely resected stage IIIA 
NSCLC. 
Methods: This trial was initiated by the Lung Cancer Research Team 
at Korea Cancer Center Hospital March 1989, and enrollment was 
stopped December 1998. It was designed as a randomized, prospec-
tive three-armed study with surgery only (control group, 55 patients) 
versus surgery plus adjuvant radiotherapy (study group I, 56 patients) 
and surgery plus adjuvant MVP (mitomycin C, vinblastin and cisplatin) 
chemotherapy (study group II, 53 patients). 
Results: Data for all the patients were complete after long-term follow-
up. Thirty-eight patients in the control group, thirty patients in the study 
group I and twenty-nine patients in the study group II experienced 
tumor recurrence during follow-up. The median times of disease-free 
were 16.3 months (control group), 35.3 months (study group I), and 
36.6 months (study group II). The 5-year disease-free survival rates 
were 28.9%, 41.1% and 49.4%, respectively (p=0.10, log-rank test). 
Even though there was no signiﬁcant difference statistically, log-rank 
test for trend of disease-free survival was signiﬁcant (p=0.039). Only 
twelve patients (control group), nine patients (study group I), and 
sixteen patients (study group II) were survived until the end of follow-
up. The median survival times were 31.8 months (control group), 27.0 
months (study group I), and 55.7 months (study group II). The 5-year 
overall survival rates were 29.8 %, 37.5% and 48.1 %, respectively 
(p=0.22, log-rank test).
Conclusions: Our results suggest that the addition of adjuvant radio-
therapy or adjuvant MVP chemotherapy may not reduce the incidence 
of recurrence and prolong the disease-free or overall survival rates of 
the patients with stage IIIA NSCLC after surgery.
P2-203 NSCLC: Combined Modality Therapy Posters, Tue, Sept 4 
Cisplatin/Gemcitabine followed by Cisplatin/Etoposide and 
concurrent thoracic radiotherapy in patients with irresectable or 
medically inoperable non-small-cell lung cancer 
Phernambucq, Erik C.1 Spoelstra, Femke O.2 Senan, Suresh2 Paul, 
Marinus A.3 Melissant, Christian F.4 Postmus, Pieter E.1 Smit, Egbert 
F.1 
1 Department of Pulmonary Diseases, VU University Medical Center, 
Amsterdam, The Netherlands 2 Dept. of Radiotherapy, VU Medical 
Center, Amsterdam, The Netherlands 3 Dept. of Surgery, VU Medical 
Center, Amsterdam, The Netherlands 4 Dept. of Pulmonary Diseases, 
Spaarne Hospital, Hoofddorp, The Netherlands 
Aim: Retrospective analysis of treatment with cisplatin/gemcitabine 
followed by cisplatin/etoposide and concurrent thoracic radiotherapy 
(TRT) for patients with irresectable or medically inoperable non-small-
cell lung cancer (NSCLC).
Methods: Stage III NSCLC patients received one course of cisplatin 
(80mg/m2, day 1) and gemcitabine (1250mg/m2, day 1 and 8) followed 
by cisplatin (80mg/m2, day 21 and 42) and etoposide (100mg/m2, days 
21-23 and 42-44). Concurrent TRT commenced on day 22, 5 days/week 
for 5 weeks. National Cancer Institute of Canada grading system v3.0 
was used for evaluation of toxicity. Radiological response was evalu-
ated using RECIST criteria. Patients with potentially resectable stage 
III NSCLC and good performance status underwent mediastinal restag-
ing after 46-50 Gy followed by surgery if no N2-disease or distant 
metastatic disease was found. All others received radiotherapy to a total 
dose of 50-60 Gy.
Results: A total of 57 patients were treated between October 2003 and 
December 2006. Of those, 5 had medically inoperable stage IIA (1) 
and IIB (4), 24 stage IIIA, 25 stage IIIB and 3 patients with stage IV 
NSCLC. Prior treatments for NSCLC in 14 patients included pneu-
monectomy (3), (bi)lobectomy (9), stereotactic radiotherapy (1) and 
chemotherapy (6). During 178 evaluable courses of chemotherapy 
(total 179 courses), grade III/IV anemia was reported in 6 courses 
(3.4%), grade III/IV thrombocytopenia in 22 courses (12.4%) and grade 
III/IV leucocytopenia in 65 courses (36.5%). One patient died of grade 
V febrile neutropenia and one patient died as a result of lung bleeding 
after 6 Gy. Transfusions for anemia were necessary after 12 courses and 
hospitalisation for neutropenic fever in 7 cases. Carboplatin replaced 
